157 related articles for article (PubMed ID: 21293502)
1. Clostridium difficile infection in 2010: advances in pathogenesis, diagnosis and management of CDI.
Gerding DN; Johnson S
Nat Rev Gastroenterol Hepatol; 2011 Feb; 8(2):67-8. PubMed ID: 21293502
[TBL] [Abstract][Full Text] [Related]
2. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.
Koon HW; Shih DQ; Hing TC; Yoo JH; Ho S; Chen X; Kelly CP; Targan SR; Pothoulakis C
Antimicrob Agents Chemother; 2013 Jul; 57(7):3214-23. PubMed ID: 23629713
[TBL] [Abstract][Full Text] [Related]
3. Treatment with monoclonal antibodies against Clostridium difficile toxins.
Lowy I; Molrine DC; Leav BA; Blair BM; Baxter R; Gerding DN; Nichol G; Thomas WD; Leney M; Sloan S; Hay CA; Ambrosino DM
N Engl J Med; 2010 Jan; 362(3):197-205. PubMed ID: 20089970
[TBL] [Abstract][Full Text] [Related]
4. Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection.
Kvach EJ; Ferguson D; Riska PF; Landry ML
J Clin Microbiol; 2010 Jan; 48(1):109-14. PubMed ID: 19864479
[TBL] [Abstract][Full Text] [Related]
5. Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.
Koon HW; Ho S; Hing TC; Cheng M; Chen X; Ichikawa Y; Kelly CP; Pothoulakis C
Antimicrob Agents Chemother; 2014 Aug; 58(8):4642-50. PubMed ID: 24890583
[TBL] [Abstract][Full Text] [Related]
6. Mouse relapse model of Clostridium difficile infection.
Sun X; Wang H; Zhang Y; Chen K; Davis B; Feng H
Infect Immun; 2011 Jul; 79(7):2856-64. PubMed ID: 21576341
[TBL] [Abstract][Full Text] [Related]
7. Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.
Hussack G; Tanha J
Toxins (Basel); 2010 May; 2(5):998-1018. PubMed ID: 22069622
[TBL] [Abstract][Full Text] [Related]
8. Trends in the use of laboratory tests for the diagnosis of Clostridium difficile infection and association with incidence rates in Quebec, Canada, 2010-2014.
Bogaty C; Lévesque S; Garenc C; Frenette C; Bolduc D; Galarneau LA; Lalancette C; Loo V; Tremblay C; Trudeau M; Vachon J; Dionne M; Villeneuve J; Longtin J; Longtin Y;
Am J Infect Control; 2017 Sep; 45(9):964-968. PubMed ID: 28549882
[TBL] [Abstract][Full Text] [Related]
9. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.
Steele J; Mukherjee J; Parry N; Tzipori S
J Infect Dis; 2013 Jan; 207(2):323-30. PubMed ID: 23125448
[TBL] [Abstract][Full Text] [Related]
10. The roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model.
Steele J; Parry N; Tzipori S
Gut Microbes; 2014; 5(1):53-7. PubMed ID: 24394234
[TBL] [Abstract][Full Text] [Related]
11. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.
Marozsan AJ; Ma D; Nagashima KA; Kennedy BJ; Kang YK; Arrigale RR; Donovan GP; Magargal WW; Maddon PJ; Olson WC
J Infect Dis; 2012 Sep; 206(5):706-13. PubMed ID: 22732923
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
[TBL] [Abstract][Full Text] [Related]
13. [Clostridium difficile infection: epidemiology, risk factors, pathogenesis, clinical features, diagnosis and therapy].
Kılıç A
Mikrobiyol Bul; 2013 Jul; 47(3):556-66. PubMed ID: 23971935
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Nested Polymerase Chain Reaction and Immunoassay for Rapid Diagnosis of Clostridium difficile in Children with Community Acquired Diarrhea.
Elewa A; Sayed-Zaki ME
Clin Lab; 2017 Feb; 63(2):321-326. PubMed ID: 28182338
[TBL] [Abstract][Full Text] [Related]
15. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
Lancaster JW; Matthews SJ
Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
[TBL] [Abstract][Full Text] [Related]
16. Clostridium difficile infection in older adults: a review and update on its management.
Kee VR
Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
[TBL] [Abstract][Full Text] [Related]
17. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).
Leav BA; Blair B; Leney M; Knauber M; Reilly C; Lowy I; Gerding DN; Kelly CP; Katchar K; Baxter R; Ambrosino D; Molrine D
Vaccine; 2010 Jan; 28(4):965-9. PubMed ID: 19941990
[TBL] [Abstract][Full Text] [Related]
18. Glutamate dehydrogenase for laboratory diagnosis of Clostridium difficile infection.
Goldenberg SD; Cliff PR; French GL
J Clin Microbiol; 2010 Aug; 48(8):3050-1; author reply 3051. PubMed ID: 20668302
[No Abstract] [Full Text] [Related]
19. IgG antibody response to toxins A and B in patients with Clostridium difficile infection.
Wullt M; Norén T; Ljungh A; Åkerlund T
Clin Vaccine Immunol; 2012 Sep; 19(9):1552-4. PubMed ID: 22787196
[TBL] [Abstract][Full Text] [Related]
20. Rapid Detection of Clostridium difficile Toxins in Stool by Raman Spectroscopy.
Koya SK; Yurgelevic S; Brusatori M; Huang C; Diebel LN; Auner GW
J Surg Res; 2019 Dec; 244():111-116. PubMed ID: 31279995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
